2025

Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.
Carnero Contentti, Edgar ORCID: https://orcid.org/0000-0001-7435-5726, de Oliveira Boldrini, Vinícius ORCID: https://orcid.org/0000-0003-3984-2689, Casallas-Vanegas, Adriana ORCID: https://orcid.org/0000-0003-4711-8148, Gluscevic, Sanja ORCID: https://orcid.org/0000-0002-9230-9093, Koc, Emine Rabia ORCID: https://orcid.org/0000-0002-0264-7284, Samadzadeh, Sara ORCID: https://orcid.org/0000-0003-3593-1852, Seferoğlu, Meral ORCID: https://orcid.org/0000-0003-3858-0306, Szejko, Natalia ORCID: https://orcid.org/0000-0001-6160-9221 and Levy, Michael ORCID: https://orcid.org/0000-0002-7969-8346
Expert Opinion on Emerging Drugs 30 (4): 283-297. December 2025

2020

Emerging drugs for the treatment of neuromyelitis optica.
Duchow, A., Chien, C. ORCID: https://orcid.org/0000-0001-8280-9513, Paul, F. ORCID: https://orcid.org/0000-0002-6378-0070 and Bellmann-Strobl, J. ORCID: https://orcid.org/0000-0003-2615-1643
Expert Opinion on Emerging Drugs 25 (3): 285-297. September 2020

2011

Emerging drugs which target the renin-angiotensin-aldosterone system.
Steckelings, U.M., Paulis, L., Unger, T. and Bader, M. ORCID: https://orcid.org/0000-0003-4780-4164
Expert Opinion on Emerging Drugs 16 (4): 619-630. December 2011